Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Palisade Bio Inc
(NQ:
PALI
)
3.940
+0.230 (+6.20%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Palisade Bio Inc
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
January 11, 2023
Via
ACCESSWIRE
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
December 07, 2022
From
Palisade Bio, Inc.
Via
GlobeNewswire
Palisade Bio Regains Compliance with Nasdaq Listing Requirements
December 01, 2022
From
Palisade Bio, Inc.
Via
GlobeNewswire
Palisade Bio (NASDAQ: PALI) Awarded Fast Track Designation from U.S. FDA for LB1148
November 22, 2022
Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of
Via
Spotlight Growth
Exposures
Product Safety
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
November 22, 2022
From
Palisade Bio, Inc.
Via
GlobeNewswire
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
November 18, 2022
From
Palisade Bio, Inc.
Via
GlobeNewswire
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
November 17, 2022
From
Palisade Bio, Inc.
Via
GlobeNewswire
Palisade Bio Announces Reverse Stock Split
November 15, 2022
From
Palisade Bio, Inc.
Via
GlobeNewswire
Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022
From
Palisade Bio, Inc.
Via
GlobeNewswire
Palisade Bio Announces Executive Leadership Transition
October 11, 2022
From
Palisade Bio, Inc.
Via
GlobeNewswire
Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022
September 29, 2022
From
Palisade Bio, Inc.
Via
GlobeNewswire
Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners
March 14, 2022
Dallas, Texas--(Newsfile Corp. - March 14, 2022) - Stonegate Capital Partners is hosting a...
Via
Newsfile
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.